JPWO2020252383A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020252383A5
JPWO2020252383A5 JP2021573446A JP2021573446A JPWO2020252383A5 JP WO2020252383 A5 JPWO2020252383 A5 JP WO2020252383A5 JP 2021573446 A JP2021573446 A JP 2021573446A JP 2021573446 A JP2021573446 A JP 2021573446A JP WO2020252383 A5 JPWO2020252383 A5 JP WO2020252383A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
cycloalkyl
haloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537140A5 (https=
JP2022537140A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037591 external-priority patent/WO2020252383A2/en
Publication of JP2022537140A publication Critical patent/JP2022537140A/ja
Publication of JP2022537140A5 publication Critical patent/JP2022537140A5/ja
Publication of JPWO2020252383A5 publication Critical patent/JPWO2020252383A5/ja
Pending legal-status Critical Current

Links

JP2021573446A 2019-06-14 2020-06-12 プロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）の調節のための化合物 Pending JP2022537140A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861902P 2019-06-14 2019-06-14
US62/861,902 2019-06-14
PCT/US2020/037591 WO2020252383A2 (en) 2019-06-14 2020-06-12 Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)

Publications (3)

Publication Number Publication Date
JP2022537140A JP2022537140A (ja) 2022-08-24
JP2022537140A5 JP2022537140A5 (https=) 2023-06-19
JPWO2020252383A5 true JPWO2020252383A5 (https=) 2023-06-19

Family

ID=73780709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573446A Pending JP2022537140A (ja) 2019-06-14 2020-06-12 プロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）の調節のための化合物

Country Status (8)

Country Link
US (1) US20220267269A1 (https=)
EP (1) EP3983392A4 (https=)
JP (1) JP2022537140A (https=)
CN (1) CN114206843A (https=)
AU (1) AU2020291468A1 (https=)
CA (1) CA3142890A1 (https=)
IL (1) IL288848A (https=)
WO (1) WO2020252383A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN121443616A (zh) * 2023-07-27 2026-01-30 上海拓界生物医药科技有限公司 二氨基环戊基取代的杂芳基衍生物及其用途和制备方法
WO2025034510A1 (en) 2023-08-04 2025-02-13 University Of Rochester Adrenergic antagonists for use in a method for treating cerebral edema or a brain injury

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556990A (en) * 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
WO2000071107A2 (en) * 1999-05-21 2000-11-30 Pfizer Products Inc. New pharmaceutical combinations for nos inhibitors
JP4866610B2 (ja) * 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
EP1957477B1 (en) * 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PT2057153E (pt) * 2006-07-10 2012-11-14 Lundbeck & Co As H Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina
HK1257102A1 (zh) * 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
CN106995413A (zh) * 2016-01-25 2017-08-01 中国科学院大连化学物理研究所 一种铱催化氢化不对称合成哌嗪衍生物的方法
WO2018165718A1 (en) * 2017-03-17 2018-09-20 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
CN110546149B (zh) * 2017-04-21 2022-11-11 深圳信立泰药业股份有限公司 作为pcsk9抑制剂的哌啶类化合物

Similar Documents

Publication Publication Date Title
RU2404189C9 (ru) Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита c
JPWO2023099592A5 (https=)
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2018515495A5 (https=)
JP2006501295A5 (https=)
JP2013544812A5 (https=)
JP2020507589A5 (https=)
JP2005504042A5 (https=)
JP2018521092A5 (https=)
JP2005523922A5 (https=)
JP2016518437A5 (https=)
JP2015509535A5 (https=)
JP2009537550A5 (https=)
JP2006182786A5 (https=)
JP2020122016A5 (https=)
JP2020511536A5 (https=)
JP2011509302A5 (https=)
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2007504235A5 (https=)
JP2019501927A5 (https=)
JPWO2020252383A5 (https=)
JPWO2022212489A5 (https=)
JP2021529203A5 (https=)
JP2007509052A5 (https=)